Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130(4):1653-1668.

Matrai C, Motanagh S, Mirabelli S, Ma L, He B, Chapman-Davis E, et al. Molecular Profiles of Mixed Endometrial Carcinoma. Am J Surg Pathol. 2020;44(8):1104-1111.

Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, et al. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. Eur Urol Open Sci. 2020;22:34-44.

Lu Y, Lin M, Zong J, Zong L, Zhao Z, Wang S, et al. Highly bioavailable curcumin preparation with a co-grinding and solvent-free process. Food Sci Nutr. 2020;8(12):6415-6425.

Wang R, Vemulapati S, Westblade LF, Glesby MJ, Mehta S, Erickson D. cAST: Capillary-Based Platform for Real-Time Phenotypic Antimicrobial Susceptibility Testing. Anal Chem. 2020;92(3):2731-2738.

Haas M, Seshan SV, Barisoni L, Amann K, Bajema IM, Becker JU, et al. Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society. Kidney Int. 2020;98(5):1120-1134.

Nanayakkara J, Tyryshkin K, Yang X, Wong JJ, Vanderbeck K, Ginter PS, et al. Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. NAR Cancer. 2020;2(3):zcaa009.

Kim J-, Yang Y-, Park KH, Ge X, Xu R, Li N, et al. A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nat Commun. 2020;11(1):2289.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2020;25(2):140-149.

Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.